Treatment of facial rhytides with a nonablative 1,450-nm diode laser: a controlled clinical and histologic study.

OBJECTIVE: To evaluate the safety and effectiveness of a nonablative 1,450-nm midinfrared diode laser in the treatment of facial rhytides. METHODS: Twenty-five patients (skin phototypes I-III) with mild-to-moderate perioral or periorbital rhytides received four successive treatments at 3- to 4-week intervals with a 1,450-nm diode laser (SmoothBeam; Candela Corp., Wayland, MA). Symmetrical matched areas were left untreated to serve as controls. Patients were evaluated with digital photography at each treatment session and at 1, 3, 6, and 12 months after the final laser treatment. Skin biopsies were obtained from treatment and control facial sites for histologic evaluation before treatment, immediately after the first treatment, and 3, 6, and 12 months after the fourth treatment. Patient satisfaction scores were obtained at each follow-up visit. RESULTS: Mild to moderate improvement in treated facial rhytides was observed in all patients. Increased dermal collagen was seen 6 months after four successive treatments. Patient satisfaction scores paralleled the photographic and histopathologic changes seen. Side effects were limited to transient erythema, edema, and postinflammatory hyperpigmentation. CONCLUSION: The nonablative 1,450-nm diode laser is safe and effective for the treatment of mild-to-moderate facial rhytides.

Nonablative laser skin resurfacing using a 1540 nm erbium glass laser: a clinical and histologic analysis.

BACKGROUND: A variety of laser systems have recently become available that allow for selective dermal remodeling without disruption of the epidermal surface. Modest clinical improvement in mild to moderate photoinduced facial rhytides with minimal morbidity is typical of these nonablative lasers, providing a significant advantage over traditional ablative laser systems. OBJECTIVE: To determine the clinical and histologic effects of a novel 1540 nm erbium glass laser on facial rhytides. METHODS: Patients with mild to moderate periorbital and perioral rhytides received a series of three monthly treatments with a 1540-nm erbium-doped phosphate glass laser by a single operator. Photographic and clinical evaluations were independently conducted by the patient and a masked medical observer at each treatment visit and at 1, 3, and 6 months following the final treatment session. Skin biopsies were obtained for histologic analysis by a board-certified dermatopathologist at baseline, immediately following laser irradiation, and at one and six months post-treatment. RESULTS: Slow, progressive clinical improvement of rhytides was noted in all patients after each treatment and continued throughout the extended follow-up period. Side effects of treatment were limited to transient erythema and edema immediately following laser irradiation. No serious adverse effects were noted. Histologic skin changes were not apparent until several months following treatment, when an increase in dermal collagen was noted. CONCLUSIONS: The nonablative 1540 nm erbium glass laser system with contact cooling produces gradual clinical and histologic improvement in mild to moderate facial rhytides with minimal risk of serious adverse sequelae.